Another meta-analysis comparing nine diabetic drug classes recently found that in patients with T2DM at increased cardiovascular risk on metformin-based background treatment, GLP-1 RAs and SGLT2 inhibitors stood apart as reducing all-cause mortality and cardiovascular death [61]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.